使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to the third-quarter 2026 financial results conference call and webcast for Zoetis. Hosting the call today is Mathieu Aussermeier, Senior Vice President, Corporate Finance for Zoetis.
歡迎收聽 Zoetis 2026 年第三季財務業績電話會議與網路直播。今天的會議由 Zoetis 企業財務資深副總裁 Mathieu Aussermeier 主持。
Presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com. (Operator Instructions)
簡報資料與其他財務表格目前已張貼於 zoetis.com 的投資人關係專區。簡報投影片可由您(觀眾)自行操作,且不會自動往前播放。此外,本次電話會議結束約兩小時後,可透過撥入電話或至 zoetis.com 的投資人關係專區收聽重播。(接線員指示)
It is now my pleasure to turn the call over to Mathieu Aussermeier. You may begin.
現在我很高興將電話會議交給 Mathieu Aussermeier。您可以開始了。
Mathieu Aussermeier - Senior Vice President, Corporate Finance
Mathieu Aussermeier - Senior Vice President, Corporate Finance
Thank you, operator. Good morning, everyone, and welcome to the Zoetis third-quarter 2026 earnings call.
謝謝,接線員。各位早安,歡迎參加 Zoetis 2026 年第三季財報電話會議。
I am joined today by Kristin Peck, Chief Executive Officer, and Jay Saccaro, Chief Financial Officer and Chief Operating Officer. This morning, we issued a press release announcing our third-quarter 2026 financial results.
今天與我一同出席的有執行長 Kristin Peck,以及財務長兼營運長 Jay Saccaro。今天早上,我們發布新聞稿,公布 2026 年第三季財務結果。
Before we begin, I would like to remind you that the release and corresponding earnings presentation, which we will reference during this call, are available on the Investor Relations section of our website, and that many of our statements today may be considered forward-looking statements, and that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and in our company's Exchange Act reports filed with the SEC.
在開始之前,我想提醒各位:本次電話會議將引用的新聞稿與相對應的財報簡報已可於本公司網站的投資人關係專區取得;此外,我們今天的許多陳述可能構成前瞻性陳述,而實際結果可能與這些預測有重大差異。關於可能導致結果不同的若干因素之清單與說明,請參閱今日新聞稿中的前瞻性陳述,以及本公司向美國證券交易委員會(SEC)提交的《交易法》報告。
Additionally, today's remarks will include certain non-GAAP financial measures. Reconciliation of these non-GAAP financial measures to the most directly comparable US GAAP measures can be found in our earnings press release and our company's 8-K filing dated today, November 5, 2026. We will also reference reported and organic operational growth. Organic operational growth excludes the effect of foreign currency, as well as acquisitions and divestitures, which individually impact Zoetis' growth by 1% or more. Unless otherwise stated, all revenue growth performance metrics will be based on organic operational performance.
此外,今天的發言將包含若干非 GAAP 財務衡量指標。這些非 GAAP 財務衡量指標與最直接可比的美國 GAAP 指標之調節表,可見於我們的財報新聞稿,以及本公司於今日(2026 年 11 月 5 日)提交的 8-K 文件。我們也將提及報告基礎與有機營運成長。有機營運成長排除外幣影響,以及併購與處分的影響(單一項目對 Zoetis 成長的影響達 1% 或以上者)。除非另有說明,所有營收成長表現指標將以有機營運表現為基礎。
With that, I will turn the call over to Kristin. Kristin?
接下來,我把電話會議交給 Kristin。Kristin?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Thank you, Mathieu. Good morning, everyone, and thank you for joining us.
謝謝你,Mathieu。各位早安,感謝各位加入我們。
Today, we reported our third quarter results with revenue and adjusted net income both declining in line with our expectations. Our diversified portfolio provided some resilience, and we focused on defending leadership positions with investments in key franchises. At the same time, we continued advancing the portfolio and innovation pipeline. While challenging dynamics are continuing, we are seeing progress in the actions we are taking and have narrowed our full-year revenue guidance to the high end of our range.
今天,我們公布第三季業績,營收與調整後淨利均如我們預期般下滑。我們多元化的產品組合提供了一定的韌性,我們也專注於透過對關鍵產品線的投資來捍衛領導地位。同時,我們持續推進產品組合與創新研發管線。儘管具挑戰性的態勢仍在延續,我們已看到所採取行動的進展,並將全年營收指引收斂至區間的高端。
As I walk you through our performance, I want to put the industry and company results in perspective and outline how we are positioning Zoetis for the near and long term. But first, I am pleased to welcome Jay to his first earnings call with Zoetis. He brings a strong track record and a valuable combination of financial and operating experience, and we're excited to have him on the team. With that, let me start with what we see across the industry.
在我帶各位回顧我們的表現時,我希望從更宏觀的角度看待產業與公司結果,並說明我們如何為 Zoetis 的短期與長期發展進行布局。但首先,我很高興歡迎 Jay 參加他加入 Zoetis 後的首次財報電話會議。他擁有亮眼的實績,以及財務與營運經驗兼具的寶貴組合,我們很高興他加入團隊。接下來,先從我們在整體產業所觀察到的情況談起。
As you all know, animal health remains a long-term secular growth industry, driven by a growing global population looking to eat more protein and adopt and care for more pets. Like most industries, however, animal health is not immune to cyclical factors, which affect pet care and livestock differently. In developed pet care markets, veterinary service costs have risen 50% since 2022, well ahead of general inflation. Alongside softer consumer confidence, that cost pressure is making pet owners more value-conscious and deliberate when making trade-offs to care for their pets. The mix of pets is also changing.
各位都知道,動物保健仍是長期的結構性成長產業,成長動能來自全球人口增加、對更多蛋白質的需求,以及更多人飼養並照護寵物。然而,如同多數產業,動物保健也無法免於景氣循環因素的影響,而這些因素對寵物照護與畜牧的影響並不相同。在已開發的寵物照護市場,自 2022 年以來,獸醫服務成本已上升 50%,遠高於整體通膨。在消費者信心轉弱的同時,成本壓力使飼主在照護寵物時更重視性價比,並在取捨上更為審慎。寵物的組成結構也正在改變。
High housing costs are affecting homeownership and pet adoption, with fewer dogs joining households as cat ownership continues to grow. Because dogs are more medicalized than cats, this shift also affects underlying demand for veterinary services. These pressures are reflected in the continued weakness in US clinic visits, which are down 3% year-to-date across categories. These dynamics, combined with intense competition in key franchises, continue to weigh on our companion animal revenue this quarter. At the same time, the bond between people and their pets remains strong.
高房價正在影響購屋與寵物領養,進入家庭的狗隻減少,而養貓比例持續上升。由於狗的醫療化程度高於貓,這種轉變也會影響獸醫服務的基礎需求。這些壓力反映在美國診所就診次數持續疲弱上:年初至今各類別合計下降 3%。這些動態再加上關鍵產品線的激烈競爭,持續拖累我們本季的伴侶動物營收。同時,人與寵物之間的連結依然強韌。
In the US, the Human Animal Bond Research Institute's latest survey found that 98% of pet owners experience health benefits from their pets, and 91% said knowing about those benefits makes them more likely to maintain their pet's health. That enduring bond is an important foundation for our industry, but it exists alongside real barriers. 37% of people planning to get a pet cited the cost of ownership as a concern.
在美國,人寵關係研究機構(Human Animal Bond Research Institute)最新調查發現,98% 的飼主從寵物身上獲得健康益處,且 91% 表示了解這些益處後,更可能維持寵物的健康。這種長久的連結是本產業的重要基礎,但同時也伴隨著真實存在的障礙。在計畫飼養寵物的人當中,有 37% 將飼養成本列為顧慮。
As the industry leader, we are focused on meeting customers where they are. That means working with veterinary practices to support their profitability and success while developing programs to help pet owners manage the cost of care. In contrast, livestock is benefiting from growing demand for quality protein sources.
作為產業領導者,我們專注於在客戶所在之處與其相遇。這意味著與獸醫診所合作,支持其獲利能力與成功,同時開發計畫協助飼主管理照護成本。相較之下,畜牧業正受惠於對高品質蛋白質來源日益成長的需求。
We're also seeing growing demand on animal health to improve productivity, support food security, and adopt a One Health approach. That demand has contributed to historic industry growth, and for Zoetis, underscores the strength of a broad and diverse portfolio. While we expect livestock to remain a strong contributor over the short, medium, and long term, disease, weather, and local production cycles will continue to influence year-to-year results.
我們也看到動物保健在提升生產力、支持糧食安全,以及採行「同一健康(One Health)」方法方面的需求正在增加。這些需求促成了產業的歷史性成長,對 Zoetis 而言,也凸顯廣泛且多元產品組合的優勢。雖然我們預期畜牧在短期、中期與長期都將持續是重要貢獻者,但疾病、天候與在地生產週期仍將持續影響逐年表現。
Diversity matters, not only across species, but across geographies. Growth conditions vary significantly from market to market, reflecting differences in economic and geopolitical conditions, species mix, and regulatory environment. In many developed markets, pet care represents a larger and more medicalized share of the animal health market, while in many emerging markets, livestock does.
多元化很重要,不僅體現在物種之間,也體現在不同地理區域之間。各市場的成長條件差異顯著,反映經濟與地緣政治情勢、物種組合與法規環境的不同。在許多已開發市場中,寵物照護在動物保健市場中占比更高且醫療化程度更深;而在許多新興市場,畜牧則占比較高。
As a result, the same economic shifts can affect markets in very different ways. Tariffs and trade flows continue to evolve, and our commercial strategies reflect the conditions in each market. That local focus matters because emerging markets are expected to remain the fastest-growing part of animal health, with room to bring more animals into regular care, gain share, and broaden access to innovation which brings me to what we're doing to defend and grow our leadership.
因此,相同的經濟變化可能以截然不同的方式影響各個市場。關稅與貿易流向仍在演變,我們的商業策略也會反映各市場的條件。這種在地化聚焦之所以重要,是因為新興市場預期仍將是動物保健成長最快的部分,且仍有空間讓更多動物納入定期照護、提升市占,並擴大創新可及性——這也帶到我們如何捍衛並擴大領導地位。
Building on the actions we've outlined over the past two quarters, today, I'll focus on three priorities: leveraging the diversity of our portfolio, expanding access to established franchises, and advancing innovation.
延續我們在過去兩季所說明的行動,今天我將聚焦三項優先事項:發揮我們產品組合的多元性、擴大既有核心產品線的可及性,以及推進創新。
I'll take you through each with examples of how they're showing up across our key franchises. First, we're leveraging the advantage that comes from the diversity and differentiation of our portfolio. Competition is increasingly playing out product by product, but our range of options within the therapeutic categories and across channels gives us more ways to meet customer needs and compete effectively. Those choices are especially important in our key dermatology franchise, where share pressure is most acute.
我將逐一說明,並舉例說明這些策略如何在我們的關鍵產品線中展現。首先,我們正運用來自產品組合多元性與差異化所帶來的優勢。競爭愈來愈以單一產品為單位展開,但我們在治療領域內以及跨通路所提供的多樣選擇,讓我們有更多方式滿足客戶需求並有效競爭。這些選擇在我們的關鍵皮膚科產品線中特別重要,因為該領域的市占壓力最為明顯。
We are continuing to sharpen commercial execution, directing resources where they can influence customer decisions, and reinforcing the value of our differentiated portfolio with vets and pet owners. For example, we're using that breadth to drive conversion to Apoquel Chew with a chew-in-the-room promotion and in-clinic sampling, highlighting a more convenient alternative that can support treatment compliance.
我們持續強化商業執行力,將資源導向能影響客戶決策之處,並與獸醫及寵物飼主共同強化我們差異化產品組合的價值。例如,我們正運用這項廣度,透過「診間咀嚼錠促銷」與院內試用取樣,推動轉換至 Apoquel Chew,突顯更便利的替代方案,以支持治療依從性。
At the same time, we expect US approval of long-acting Cytopoint in the fourth quarter, adding a more convenient option for chronic itch, a segment that accounts for more than 60% of global dermatology doses. We're using that added diversity to build awareness for the next option in derm, with a teaser campaign ahead of approval.
同時,我們預期長效型 Cytopoint 將於第四季在美國獲准,為慢性搔癢提供更便利的選擇;慢性搔癢所屬的細分市場占全球皮膚科劑量逾 60%。我們正運用新增的多元性,在核准前透過前導(teaser)宣傳活動,為皮膚科的下一個選項建立認知。
Similarly, since the beginning of the year, we faced mounting generic competition for Convenia and Cerenia. We acted swiftly, and this quarter, we saw the pace of share gains moderate for the first time since entry. With recent FDA approval in the US and its coming launch in Canada, Convenia RTU for dogs extends the portfolio with a single injection that can provide up to 14 days of treatment.
同樣地,自年初以來,我們面臨 Convenia 與 Cerenia 的學名藥競爭加劇。我們迅速採取行動,本季我們看到市占提升的速度自進入以來首次趨緩。隨著近期在美國獲 FDA 核准,並即將在加拿大上市,犬用 Convenia RTU 以單次注射即可提供最長 14 天治療,擴充了產品組合。
Second, we're expanding access to our established franchises and investing in the evidence and medical support that help vets navigate a more selective market. When visits are down and owners are weighing the cost of care, the clinical conversation matters. Veterinarians need to identify patients who can benefit and have relevant evidence to support treatment decisions. This is a central role of medical affairs, and one reason we launched the Medical Hub, which houses our scientific insights, publications, and educational materials in one place for veterinary teams.
第二,我們正擴大既有核心產品線的可及性,並投資於證據與醫學支援,協助獸醫在更為挑剔的市場中做出判斷。當就診次數下降、飼主在衡量照護成本時,臨床對話就格外重要。獸醫需要辨識可能受益的病患,並具備相關證據以支持治療決策。這是醫學事務的核心職能之一,也是我們推出 Medical Hub 的原因;該平台將我們的科學洞見、出版物與教育素材集中於一處,供獸醫團隊使用。
That approach is relevant in parasiticides, where softer end market demand is creating pressure. Even with double-digit declines in US flea, tick, and heartworm clinic visits, the Simparica franchise delivered modest growth this quarter, as expanded access to Simparica Trio drove growth internationally. Trio's triple combination protection gives vets a differentiated option, supported by recent peer-reviewed research on heartworm resistance.
這種作法同樣適用於寄生蟲防治藥物領域,因終端市場需求走弱而形成壓力。即便美國跳蚤、壁蝨與心絲蟲相關門診就診次數出現兩位數下滑,Simparica 產品線本季仍實現小幅成長,原因在於擴大 Simparica Trio 的可及性帶動國際成長。Trio 的三合一防護為獸醫提供差異化選擇,並有近期同儕審查研究(peer-reviewed)關於心絲蟲抗藥性的支持。
One example of scientific evidence supporting the franchise is a recent peer-reviewed speed of kill study available through the Medical Hub, and our continued investments in Phase IV studies provide vets with relevant evidence in a more selective market.
支持該產品線的科學證據之一,是近期一項經同儕審查的「殺滅速度」研究,可透過 Medical Hub 取得;而我們持續投入第四期(Phase IV)研究,亦為獸醫在更為挑剔的市場中提供相關證據。
We also now expect approval of Simparica Duo by year-end, ahead of our original timeline, broadening the portfolio and extending access to customers with unmet needs. This same strategy applies to OA pain. We're building the category, but it requires sustained effort to improve disease awareness and help veterinarians identify more patients who could benefit from treatment. We are clear-eyed about the work ahead and measured in our expectations.
我們也預期 Simparica Duo 將於年底前獲准,較原先時程提前,進一步擴大產品組合並提升對具未被滿足需求客戶的可及性。同樣策略也適用於骨關節炎(OA)疼痛。我們正在打造此一品類,但需要持續努力以提升疾病認知,並協助獸醫辨識更多可能受益於治療的病患。我們清楚了解前方仍有大量工作要做,並對預期保持審慎。
At the same time, just four years ago, alternatives to NSAIDs were limited. Today, our portfolio offers dogs and cats monthly or longer-acting three-month pain relief. Recent approvals and launches of Lenivia and Portela extend those options, and we believe broader access will build the category over time. These are strong franchises in markets we help build. Our focus is to support customers through current pressures while continuing to invest in their growth.
同時,就在四年前,非類固醇消炎藥(NSAIDs)以外的替代方案仍相當有限。如今,我們的產品組合可為犬貓提供每月一次或更長效、達三個月的疼痛緩解。Lenivia 與 Portela 近期的核准與上市擴充了這些選項,我們相信隨著可及性提升,將隨時間推進而帶動品類成長。這些是在我們協助建立的市場中具實力的產品線。我們的重點是在當前壓力下支持客戶,同時持續投資其成長。
Third, we continue to advance innovation while remaining disciplined in how we allocate capital. In this environment, that means taking costs out where needed to operate more efficiently while protecting investments in innovation and advancing our robust pipeline. Lifecycle innovation is central to the first.
第三,我們持續推進創新,同時在資本配置上保持紀律。在此環境下,這意味著在需要之處降低成本、提升營運效率,同時保護對創新的投資並推進我們強健的研發管線。產品生命週期創新是第一項的核心。
The examples I have discussed in derm, parasiticides, and OA pain strengthen established franchises and help create resilience in a pressured market. We are applying this same approach to livestock through new formulations and expanded indications across the portfolio, including FDA emergency use authorization of Dectomax for New World screwworm. These extensions help keep our portfolio relevant to evolving customer needs and support franchise contribution over time.
我在皮膚科、寄生蟲防治藥物與 OA 疼痛所討論的例子,強化了既有核心產品線,並有助於在受壓市場中建立韌性。我們也將同樣方法應用於經濟動物,透過新劑型與跨產品組合的適應症擴增,包括 Dectomax 針對新世界螺旋蛆(New World screwworm)取得 FDA 緊急使用授權。這些延伸有助於讓我們的產品組合持續貼近客戶需求的演變,並在時間推移中支持產品線的貢獻。
Last year, at our innovation webcast, we committed to achieving a significant major market approval every year for the next several years. To date, we have met our 2026 milestones, and in some areas, moved ahead of schedule. For example, Convenia RTU has now received approvals in two major markets, both earlier than planned.
去年在我們的創新網路直播中,我們承諾未來數年每年都要取得一項重要市場的重大核准。截至目前,我們已達成 2026 年的里程碑,且在部分領域進度超前。例如,Convenia RTU 現已在兩個主要市場取得核准,且皆早於原先規劃。
Beyond lifecycle innovation, we are working to create new categories in areas such as renal disease, oncology, cardiology, and obesity, where diagnosis is essential to identifying patients who may benefit from treatment. That makes diagnostics a strategic enabler of this pipeline.
除生命週期創新之外,我們也致力於在腎臟疾病、腫瘤、心臟科與肥胖等領域開創新類別;在這些領域中,診斷對於辨識可能受益於治療的病患至關重要。因此,診斷是推動此研發管線的策略性關鍵推手。
Our investments are building the tools and capabilities to support that work. This quarter, companion animal diagnostics delivered double-digit revenue growth, reflecting increased utilization and contributions from the strategic acquisitions of VitalRADS and VPG. Our market leadership was built on innovation. Sustaining it means extending the franchises we have today while building the capabilities that will enable the future of animal health.
我們的投資正在打造支持這項工作的工具與能力。本季,伴侶動物診斷業務營收實現兩位數成長,反映使用率提升,以及策略性收購 VitalRADS 與 VPG 的貢獻。我們的市場領導地位建立於創新之上。要維持領先,意味著在延伸現有產品線的同時,打造能夠支撐動物健康未來的能力。
Before I turn it over to Jay, I want to be clear that while the companion animal market remains soft in the quarter, Zoetis' targeted commercial execution has helped mitigate the macro and competitive pressures, and we will continue to adapt our approach as the market evolves. We remain focused on disciplined resource allocation paired with investments to grow markets and share.
在我把時間交給 Jay 之前,我想明確表示:雖然本季伴侶動物市場仍然疲弱,Zoetis 具針對性的商業執行已協助緩解總體與競爭壓力;我們也將隨市場演變持續調整作法。我們仍專注於在嚴謹的資源配置下,搭配投資以擴大市場與市占。
At Zoetis, that means directing resources to defend our key franchises today while advancing innovation for the future to drive strong growth over time. We have the portfolio, science, and customer relationships to do just that.
在 Zoetis,這意味著將資源導向捍衛我們當前的關鍵產品線,同時推進面向未來的創新,以在時間推移中帶動強勁成長。我們具備產品組合、科學實力與客戶關係,足以做到這一點。
With that, I am pleased to hand it over to Jay.
接下來,我很高興把時間交給 Jay。
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
Thanks, Kristin.
謝謝,Kristin。
I am excited to be here for my first earnings call with Zoetis. While I am just a few months in, my conviction in this company has only grown. The product and organization are world-class, and the innovation pipeline spanning CKD, oncology, and next-generation lifecycle products represents a real catalyst for long-term value creation.
我很高興能在 Zoetis 的首次財報電話會議中與各位見面。雖然我加入才幾個月,但我對這家公司的信心只增不減。產品與組織皆屬世界級,而涵蓋慢性腎臟病(CKD)、腫瘤學以及下一代生命週期產品的創新研發管線,將成為長期價值創造的真正催化劑。
My near-term focus is on understanding our business and operations in detail, ensuring our cost structure is as competitive as our portfolio, and working alongside Kristin and the team to navigate the current market environment with discipline and transparency. As I deepen my understanding of the business, we will also be evaluating the financial metrics we share related to guidance, and we look forward to sharing an update with you on the fourth quarter call. With that, let's look at the quarter.
我短期的重點是深入理解我們的業務與營運細節,確保我們的成本結構與產品組合同樣具競爭力,並與 Kristin 及團隊並肩合作,以紀律與透明度應對當前市場環境。隨著我對業務理解加深,我們也將評估在財測(guidance)相關方面所分享的財務指標,並期待在第四季電話會議上向各位更新。接著,我們來看本季表現。
We delivered revenue of $2.4 billion, declining 1% on both a reported and organic operational basis, in line with our expectations, driven by a 1% price decline and flat volume. Our US segment revenue was $1.2 billion, down 6%, driven by declines in companion animal from our key dermatology portfolio, as well as the impact of generics on certain brands, while our international segment was $1.1 billion, up 4%, with growth across livestock, parasiticides, and OA pain more than offsetting dermatology headwinds.
我們實現營收 24 億美元,按申報口徑與有機營運口徑均下滑 1%,符合我們的預期;主要受 1% 的價格下滑與銷量持平所致。美國區營收為 12 億美元,下滑 6%,主要由伴侶動物業務中我們關鍵皮膚科產品組合的下滑,以及學名藥對部分品牌的影響所致;國際區營收為 11 億美元,成長 4%,經濟動物、寄生蟲防治藥物與 OA 疼痛的成長,已足以抵消皮膚科的不利因素。
We delivered adjusted EPS of $1.75 in the quarter, up 1%, driven by the lower share count due to our ongoing share repurchase activity. Adjusted gross margin was 71%, down 30 basis points on a reported basis. Foreign exchange had a favorable impact of 30 basis points.
本季我們交出調整後每股盈餘(EPS)1.75 美元,年增 1%,主要受惠於持續進行庫藏股回購活動帶來的流通股數下降。調整後毛利率為 71%,以報告基礎計算下降 30 個基點。外匯對毛利率帶來 30 個基點的正面影響。
On an operational basis, gross margin was down 60 basis points, driven by the impact of our strategic pricing initiatives, product mix, and certain inventory-related charges, partially offset by refunds related to prior tariff assessments.
以營運基礎計算,毛利率下降 60 個基點,主要受我們策略性定價措施、產品組合,以及若干與庫存相關的費用影響;部分由與先前關稅評估相關的退款所抵銷。
Adjusted operating expenses were $749 million, flat operationally, with both adjusted SG&A of $571 million and adjusted R&D of $174 million also flat, reflecting the continued benefit of our cost and productivity programs, including lower incentive compensation and professional services savings, partially offset by increased R&D investments in data and digital initiatives and our broader project portfolio.
調整後營業費用為 7.49 億美元,按營運基礎持平;其中調整後銷售、一般及行政費用(SG&A)5.71 億美元與調整後研發(R&D)1.74 億美元亦同樣持平,反映我們成本與生產力計畫持續帶來效益,包括較低的獎酬支出與專業服務費用節省;部分被我們在資料與數位化計畫以及更廣泛專案組合上的研發投資增加所抵銷。
Adjusted net income was $720 million, down 7% on an organic operational basis. You will see that our GAAP results also included $78 million of an impairment charge on previously acquired in-process research and development assets, resulting from updated estimates of development and commercial assumptions.
調整後淨利為 7.20 億美元,按有機營運基礎年減 7%。你也會看到,我們的 GAAP 結果包含 7,800 萬美元的減損費用,係針對先前收購的在研研發(in-process R&D)資產,因更新對開發與商業化假設的估計而認列。
Let's look more closely at the key drivers of our revenue performance this quarter, starting with companion animal, where globally we declined 5% on $1.6 billion in revenue, driven by an 8% decline in the US and flat performance internationally. Within companion animal, our performance was driven by key dermatology, which declined 16% globally on $396 million in sales, reflecting competitive headwinds and pricing actions across both segments.
接著更仔細看看本季營收表現的關鍵驅動因素,先從伴侶動物業務開始:全球營收 16 億美元、年減 5%,主要因美國下滑 8%,國際市場表現持平。在伴侶動物中,我們的表現主要受關鍵皮膚科產品影響:全球銷售 3.96 億美元、年減 16%,反映兩大區隔皆面臨競爭逆風與定價措施的影響。
In the US, we declined 13% in the quarter on $266 million in revenue, driven by share loss in Apoquel, which was slowed by our promotional investments, partially offset by volume growth in the chewable formulation, which now represents roughly half of total Apoquel volume. Cytopoint sales also declined, reflecting canine visit declines of approximately 5% in the quarter, with pruritic visits specifically down 3%, as well as broader affordability pressures on pet owner spending.
在美國,本季營收 2.66 億美元、年減 13%,主要因 Apoquel 市占流失;我們的促銷投資使下滑趨勢有所放緩,部分被咀嚼錠劑型的銷量成長所抵銷,目前該劑型約占 Apoquel 總用量的一半。Cytopoint 銷售亦下滑,反映本季犬隻就診次數約下降 5%,其中搔癢(pruritic)相關就診特別下降 3%,以及寵物飼主支出面臨更廣泛的負擔能力壓力。
Direct competitive impact from new launches in the injectable dermatology space were minimal. Internationally, key dermatology was $130 million, down 20%, with pressure most acute in Europe, where new entrants drove volume losses across the Apoquel franchise. Cytopoint proved more resilient, given its differentiation in international markets.
注射型皮膚科領域新產品上市所帶來的直接競爭影響有限。國際市場方面,關鍵皮膚科營收 1.30 億美元、年減 20%,壓力在歐洲最為明顯,新進競爭者導致 Apoquel 產品線出現量的流失。Cytopoint 的表現相對更具韌性,因其在國際市場具差異化優勢。
In addition to declines in key dermatology, generic competition in Cerenia and Convenia continued to pressure US results. While volume declines moderated to their lowest level since generics entered the market in Q1, we continue to manage through a challenging competitive dynamic. Partially offsetting these declines, our Simparica franchise grew 1% on global revenue of $358 million. The results were mixed across our segments.
除關鍵皮膚科下滑外,Cerenia 與 Convenia 的學名藥競爭也持續對美國業績造成壓力。雖然自 Q1 學名藥進入市場以來,銷量下滑已放緩至最低水準,但我們仍在因應具挑戰性的競爭態勢。部分抵銷上述下滑的是,我們的 Simparica 產品線全球營收 3.58 億美元、成長 1%。各業務區隔的表現好壞參半。
Internationally, we grew 10% on revenue of $99 million, driven by strong Simparica Trio momentum across Europe and Latin America, partially offset by expected erosion in Simparica as customers continue transitioning to the triple combination product.
國際市場營收 9,900 萬美元、成長 10%,主要受 Simparica Trio 在歐洲與拉丁美洲的強勁動能帶動;部分被 Simparica 的預期性侵蝕所抵銷,因客戶持續轉向三合一複方產品。
In the US, the franchise declined 2% on $259 million in revenue, as accelerating declines in flea, tick, and heartworm clinic visits were partially offset by volume gains from our cross-portfolio promotion. Our OA pain meds generated $137 million in sales, increasing 2% globally.
在美國,該產品線營收 2.59 億美元、下滑 2%,原因是跳蚤、壁蝨與心絲蟲相關門診就診次數下滑加速;部分被我們跨產品組合促銷帶來的銷量成長所抵銷。我們的骨關節炎(OA)止痛藥物銷售額為 1.37 億美元,全球成長 2%。
We continue to see contributions from the launch of Lenivia and Portela in the EU and Canada, which drove 13% growth internationally on $86 million in revenue, with both products gaining traction quickly and early satisfaction scores from veterinarians and pet owners remaining exceptionally high.
我們持續看到 Lenivia 與 Portela 在歐盟與加拿大上市所帶來的貢獻,推動國際市場營收 8,600 萬美元、成長 13%;兩項產品皆迅速獲得市場採用,且獸醫與寵物飼主的早期滿意度評分仍維持在極高水準。
Meanwhile, in the US, OA pain meds contributed $51 million in total, declining 12%. Lower OA visits and ongoing safety perception headwinds weighed on Librela adoption and daily sales trends, partially offset by Solensia's resilience, supported by stable patient share and increased feline clinic visits in the quarter.
同時,在美國,OA 止痛藥物合計貢獻 5,100 萬美元,年減 12%。較低的 OA 就診量與持續的安全性觀感逆風,拖累 Librela 的採用與每日銷售趨勢;部分被 Solensia 的韌性所抵銷,其表現受穩定的病患市占以及本季貓科門診就診增加所支撐。
Companion animal diagnostics delivered $122 million in revenue, up 13% globally, with double-digit growth in both the US and internationally. Growth was driven primarily by recent acquisitions in both segments, including VitalRADS in the US and VPG in the UK and Ireland, with continued underlying adoption of our point-of-care and Imagyst platforms contributing to the remainder. Innovation across the diagnostics portfolio continues to advance, with OptiCell gaining traction in hematology and OmniMax, our next-generation point-of-care analyzer, on the horizon.
伴侶動物診斷業務營收 1.22 億美元,全球成長 13%,美國與國際市場皆呈雙位數成長。成長主要來自兩大區隔近期的併購案,包括美國的 VitalRADS,以及英國與愛爾蘭的 VPG;其餘成長則來自我們即時檢測(point-of-care)與 Imagyst 平台持續的基礎採用。診斷產品組合的創新持續推進,OptiCell 在血液學領域逐步獲得採用,而我們下一代即時檢測分析儀 OmniMax 也即將推出。
Now, moving on to livestock, which delivered $797 million, up 7%, with contributions across both the US and international. US livestock grew 5% on $266 million in revenue, supported by reliable Ceftiofur supply driving cattle performance, broad-based swine growth, and strong poultry vaccine demand. Internationally, we saw sales of $531 million and growth of 9%, led by cattle strength across the segment and outstanding fish performance, driven by higher vaccination rates in Norway.
接著看畜牧業務,本季營收 7.97 億美元、成長 7%,美國與國際市場皆有貢獻。美國畜牧營收 2.66 億美元、成長 5%,受惠於穩定的 Ceftiofur 供應帶動牛隻業務表現、豬隻業務的廣泛成長,以及家禽疫苗需求強勁。國際市場方面,營收 5.31 億美元、成長 9%,主要由各子領域的牛隻業務強勁表現帶動,並受挪威較高疫苗接種率推升的卓越水產表現所驅動。
Our capital allocation priorities remain unchanged. We will continue to invest in R&D and internal innovation, the engine of our long-term growth, while remaining disciplined in pursuing bolt-on business development opportunities. After internal reinvestment and business development, excess capital is returned to shareholders, as demonstrated by the $2.4 billion distributed in 2026 through the third quarter in the form of both buybacks and dividends.
我們的資本配置優先順序維持不變。我們將持續投資於研發與內部創新——這是我們長期成長的引擎——同時在追求補強型(bolt-on)業務開發機會時保持紀律。在內部再投資與業務開發之後,超額資本將回饋股東;2026 年截至第三季,我們已透過回購與股利合計回饋 24 億美元,即為明證。
Now, turning to our updated full-year guidance for 2026. Q3 delivered in line with our expectations, giving us the confidence to update our full-year guidance range. We are narrowing our full-year revenue guidance to $9.22 billion-$9.32 billion, representing an organic operational decline of -2% to -1% year over year. We are raising our adjusted net income guidance to $2.6 billion-$2.64 billion, representing organic operational decline of -7% to -5%. We are also raising adjusted diluted EPS to $6.25 to $6.35.
接著說明我們更新後的 2026 全年財測指引。第三季表現符合我們的預期,使我們有信心更新全年指引區間。我們將全年營收指引收斂至 92.2 億至 93.2 億美元,代表按年計算有機營運基礎下滑 -2% 至 -1%。我們將調整後淨利指引上調至 26.0 億至 26.4 億美元,代表有機營運基礎下滑 -7% 至 -5%。我們也將調整後稀釋每股盈餘(EPS)上調至 6.25 至 6.35 美元。
To close, our diverse portfolio and disciplined commercial execution continue to help us navigate an operating environment shaped by competitive pressure in our key companion animal franchises, softer clinic visits, and ongoing affordability headwinds for pet owners. But we are also seeing strength in livestock and solid momentum in diagnostics.
最後,我們多元的產品組合與嚴謹的商業執行,持續協助我們在營運環境中前行;該環境受到核心伴侶動物產品線的競爭壓力、門診就診偏弱,以及寵物飼主負擔能力逆風的影響。但我們也看到畜牧業務的強勁表現,以及診斷業務穩健的動能。
Before I turn it over to the operator, I wanted to share a brief word on 2027. While it is too early to provide specific guidance, we will plan prudently for the upcoming year. We will not be assuming improvements in the macro environment or pet owner spending trends, and we expect the competitive dynamics we have mentioned to remain a factor throughout most of the year.
在交給接線員之前,我想簡短談一下 2027 年。雖然現在提供具體指引仍為時過早,但我們將以審慎方式規劃來年。我們不會假設總體環境或寵物飼主支出趨勢會改善,並預期我們提到的競爭態勢在全年大部分時間仍將是影響因素。
At the same time, we are encouraged by the commercial strategies we are executing, and most importantly, we are excited about the innovations planned for 2027 and 2028. While we expect limited revenue contribution from these launches in 2027, their impact should build later in the year and into 2028. We look forward to sharing more about this on our Q4 call. Our focus remains on executing with discipline and positioning the business for improved performance over time.
同時,我們對正在執行的商業策略感到鼓舞;更重要的是,我們對 2027 與 2028 年規劃推出的創新產品感到振奮。雖然我們預期這些上市在 2027 年對營收的貢獻有限,但其影響應會在年內後段逐步擴大,並延續至 2028 年。我們期待在第四季電話會議上分享更多細節。我們的重點仍是以紀律執行,並讓業務在時間推移下具備改善表現的定位。
With that, I will turn it over to the operator for questions. Operator?
那麼,我會把時間交給接線員進行問答。接線員?
Operator
Operator
(Operator Instructions) Chris Schott, JPMorgan.
(接線員指示) Chris Schott,摩根大通。
Christopher Schott - Analyst
Christopher Schott - Analyst
I guess the first one for me would be great just to get additional color on the impact the promotional activities you initiated this year are having on the business. I guess specifically, I am just trying to get my hands around what areas do these seem to be gaining traction, and are there areas where you have not yet seen an impact?
我想我第一個問題是,希望能多了解一些你們今年啟動的促銷活動對業務造成的影響。更具體來說,我想掌握的是,這些活動似乎在哪些領域開始見到成效?以及是否有些領域你們尚未看到影響?
My second question was just maybe building on some of those 2027 comments that you just made. Just as you think about the various pushes and pulls, are just there any other considerations we should be keeping in mind for next year's numbers? Trying to get my hands around directionally, do you see the street in the right place with both top line and EPS currently?
我的第二個問題是,可能延伸你們剛才提到的一些 2027 年的評論。當你們思考各種拉力與推力時,對於明年的數字,還有沒有其他我們應該留意的考量?我想從方向性來理解,就目前市場對營收與 EPS 的預期而言,你們覺得華爾街的估計位置是否合理?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Great. Thanks, Chris. I will take your first question. I will let Jay take your second. As we spoke about on our last few calls, our pricing strategy is really focused on retaining volume and gaining share, and it is really focused on deliberate, analytically supported actions that are protecting list price, but really focusing on gross-to-net investments.
很好。謝謝你,Chris。我先回答你的第一個問題。第二個問題我讓 Jay 來回答。如同我們在前幾次電話會議中提到的,我們的定價策略確實聚焦在維持銷量並提升市占,並且著重於有意識、以分析支持的行動:在保護牌價(list price)的同時,更聚焦於毛額到淨額(gross-to-net)的投入。
We were quite pleased with the performance of those investments in the quarter, specifically, and some of these facts are in our slides that we shared as well. The promotional defense on derm managed to slow US dermatology share loss in the quarter to 4 points in Q3. It was about 7 points in Q2 overall in derm. So really pleased with really slowing that overall decline in share loss there.
我們對本季這些投入的表現相當滿意,尤其是其中一些事實也已放在我們分享的簡報中。在皮膚科處方藥(derm)方面,促銷防禦措施使美國皮膚科市占流失在第三季放緩至 4 個百分點;而在第二季,皮膚科整體約流失 7 個百分點。因此,我們對於能夠顯著放緩那裡整體市占下滑感到非常滿意。
As you think about how they came through in our parasiticides, we are really pleased that we held share in the quarter with Simparica Trio at a 22.5% share, and we remain the market leader in puppies, which I think is a really important future prediction of sales there. So we were very pleased. Again, we are going to stay focused and continue to watch the market as it evolves, and make sure we are targeting our investments to make sure we continue to protect share and ultimately grow it.
再談到這些措施在我們的驅寄生蟲藥(parasiticides)業務中的表現,我們很高興本季 Simparica Trio 以 22.5% 的市占守住了份額,而且我們仍是幼犬市場的領導者;我認為這對未來銷售是一個非常重要的前瞻指標。所以我們非常滿意。同樣地,我們會保持專注,並在市場演變過程中持續觀察,確保我們把投資投放在正確的目標上,以持續守住市占並最終提升市占。
Jay, do you want to take the second?
Jay,你要回答第二個問題嗎?
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
Sure. So look, we are in the middle of our budgeting process as we speak, so it is definitely too early to comment very specifically about 2027, but we did want to share some guiding principles. I think from our perspective, as we approach 2027, we are going to be conservative or prudent as we put together our numbers.
當然。你看,我們目前正在進行預算編列流程,所以現在要對 2027 年做非常具體的評論確實還太早,但我們確實想分享一些指導原則。以我們的角度來看,當我們面對 2027 年時,在編列數字時會採取保守或審慎的態度。
We have seen some macro trends over the last several quarters. We are not going to assume a market change in macro factors. We have seen some competitive dynamics, and while I think we walk away from the third quarter encouraged by the activity from a promotional and commercial standpoint, at the same time, we are not going to assume a change in competitive dynamic in 2027.
過去幾個季度我們看到一些總體趨勢。我們不會假設總體因素會出現市場性的變化。我們也看到一些競爭態勢;雖然我認為我們在第三季從促銷與商業活動的角度來看受到鼓舞,但同時,我們不會假設 2027 年的競爭動態會發生改變。
Then, finally, as I come into the role here, one of the things I have spent a lot of time on is the R&D pipeline. It is incredibly exciting the work that our teams are doing, and the impact over time is going to be substantial. At the same time, it is not going to have a huge impact in 2027. So from our perspective, we are going to be very thoughtful as we put together our plan for 2027. I am hesitant to comment on street models or anything like that, certainly at this point. We are very excited about the long-term prospects that we have, but we are going to be clear-eyed as we approach 2027.
最後,當我接任這個職務後,我投入很多時間在研發(R&D)產品線(pipeline)上。我們團隊正在做的工作令人非常振奮,長期下來的影響將會相當可觀。但同時,它在 2027 年不會帶來非常巨大的影響。因此,從我們的角度來看,在制定 2027 年計畫時,我們會非常審慎周全。我也不太願意在此時評論市場模型(street models)或類似內容。我們對長期前景非常興奮,但在面對 2027 年時,我們會保持清醒務實。
Operator
Operator
David Westenberg, Piper Sandler.
David Westenberg,Piper Sandler。
David Westenberg - Analyst
David Westenberg - Analyst
We followed parasiticides for a while from topicals, the orals, isoxazoline. There has generally been a consistent pattern that a new product will come in, it will get some new generational starts, and then the market kind of matures and normalizes. We saw this when you launched Simparica.
我們追蹤驅寄生蟲藥市場一段時間了,從外用(topicals)、口服(orals)到異噁唑啉(isoxazoline)。一般來說有一個相對一致的模式:新產品進入市場後,會帶來一些新一代的起始用戶(generational starts),然後市場會逐漸成熟並回歸常態。你們推出 Simparica 時我們也看到過這種情況。
Originally, you did take share, but NexGard kind of settled in and kind of continued to grow. Is that what we think we could see in the 2027, 2028 market with Simparica, with some of the new entrants and new categories? What would make it different, and what kind of indicators would tell you that maybe growth would normalize in that category in 2027, 2028? Again, I do not want to take away, you did grow 5% in Simparica Trio overall, but just curious on that, and I will have a follow-up.
一開始你們確實搶到市占,但 NexGard 後來也逐步站穩並持續成長。我們是否可能在 2027、2028 年的市場中,看到 Simparica 也出現類似情況——在一些新進入者與新類別出現之下?什麼因素會讓情況不同?又有哪些指標會讓你們判斷該類別在 2027、2028 年可能會回歸常態化成長?再次強調,我不是要淡化你們 Simparica Trio 整體仍成長 5%,只是想了解這點,我後面還有追問。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure, Dave. I will take that first question before your follow-up. As I said, we were pleased with the performance of Simparica in the quarter. The franchise globally did about 1%. We did about 4% growth in Trio specifically.
好的,Dave。在你追問之前,我先回答第一個問題。如我所說,我們對本季 Simparica 的表現感到滿意。該產品線在全球約成長 1%。而 Trio 具體來說約成長 4%。
As I was just talking about, we are very pleased that in the US, we are the market leader and we maintained our share at 22.5%, which is almost 2 times our next biggest competitor. I also think it is important if you think about parasiticides, just like the US from international, we are seeing significantly higher growth in international overall. I think you are seeing this because triple combination category is still in its infancy there.
如我剛才提到的,我們非常高興在美國我們是市場領導者,並且以 22.5% 的市占維持住份額,這幾乎是我們下一個最大競爭對手的兩倍。我也認為,如果你把驅寄生蟲藥的美國市場與國際市場相比,國際市場整體成長顯著更高,這點很重要。我想你看到這種情況,是因為三合一(triple combination)類別在那裡仍處於早期階段。
We are really expanding and entering new markets, so we see Trio is still early in its penetration, and we believe there is really a long runway for growth there. We are continuing to invest in innovation in this space. As we also mentioned, we are expecting approval of Simparica Duo by year end, which is ahead of its original timeline. I think this will continue to broaden our portfolio.
我們正在大幅擴張並進入新市場,因此我們認為 Trio 的滲透仍在早期,我們相信那裡仍有很長的成長跑道。我們也持續在這個領域投入創新。此外,如同我們也提到的,我們預期 Simparica Duo 會在年底前獲得核准,且進度早於原先時程。我認為這將持續擴大我們的產品組合。
I guess the way we see the market, we think there is still significant opportunity to continue to expand this market from single combinations, from topicals and collars, into triple combination, as well as to gain share. We have a very comprehensive portfolio that we think is differentiated, and we will continue to invest there.
我們對市場的看法是:仍有相當大的機會,能把市場從單一組合、從外用與項圈,擴展到三合一組合,同時也能提升市占。我們擁有非常完整、且我們認為具差異化的產品組合,我們會持續在此投入。
I will maybe move to your second question.
我接著可能轉到你的第二個問題。
David Westenberg - Analyst
David Westenberg - Analyst
Sure. Cytopoint, as you noted, has held in well. There isn't anything in the market like it right now. Befrena does have a label of four to eight weeks efficacy, looks pretty competitive as it launches in 2027. Can you walk us through both first, maybe from a defensive strategy perspective early on, and then maybe from an offensive strategy as you get your own long-acting product? Can you confirm that long-acting is still on time? I think you said Q4, you do expect approval. How fast is that to roll out? Thank you so much for taking the questions.
好的。Cytopoint 如你所提到的,表現一直維持得不錯。目前市場上沒有任何產品與它相似。Befrena 的標示適應症顯示療效可維持四到八週,看起來在 2027 年上市時競爭力相當強。你能否帶我們了解:第一,從早期防禦策略的角度;第二,當你們推出自家的長效產品後,從進攻策略的角度會怎麼做?你能確認長效產品仍按時程推進嗎?我想你說過第四季預期會獲得核准。核准後推向市場的速度會有多快?非常感謝你回答這些問題。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure. Thanks. We continue to believe that Cytopoint and the long-acting space in derm is really exciting. As we mentioned, it did fare better in the quarter. I think that's really because the customers are on it are quite pleased with the efficacy of the product overall. As you know, we did have a new entrant in that category in the US.
好的。謝謝。我們仍然相信,Cytopoint 以及皮膚科(derm)領域的長效產品空間確實令人振奮。如同我們提到的,它在本季的表現確實較佳。我認為這主要是因為使用該產品的客戶對其整體療效相當滿意。如你所知,在美國該類別確實出現了一個新的競爭者。
To date, they've had limited share given their supply challenges. What we are really excited about as we see in this category is to continue to expand it. We are expecting the approval of Cytopoint long-acting this year. We think Cytopoint will help us expand the category, honestly. It provides a more convenient option that lasts longer, which is really helpful for busy pet owners who coming in every month might be a challenge.
截至目前,由於供應方面的挑戰,他們的市占率仍然有限。我們對於在這個類別中所看到、並真正感到興奮的是,能夠持續把這個類別做大。我們預期今年 Cytopoint 長效型將獲得核准。坦白說,我們認為 Cytopoint 將有助於我們擴大這個類別。它提供了一個更便利、且維持時間更長的選項,對於忙碌、每個月要來一次可能有困難的寵物飼主來說非常有幫助。
This is part of the Zoetis strategy to continue to innovate in each of our key therapeutic areas to both make sure that we can continue to grow our share, as well as expand the market overall. We're pleased to have that product, and we look forward to launching it in the first half of next year. We are on track with Cytopoint long-acting, and we think it'll be a great addition to continue to build this brand.
這也是 Zoetis 策略的一部分:在我們各個關鍵治療領域持續創新,既確保我們能持續提升市占,同時也擴大整體市場。我們很高興擁有這項產品,也期待在明年上半年推出。Cytopoint 長效型的進度如期,我們認為它將是持續打造這個品牌的一項很棒的新增產品。
Operator
Operator
Jon Block, Stifel.
Jon Block,Stifel。
Jonathan Block - Analyst
Jonathan Block - Analyst
Jay, I am arriving at an implied 4Q 2026 organic revenue growth rate of around negative 3%, off an easy comp. Maybe just your thoughts on that, if accurate, any color. Then maybe more importantly, what does this mean for the business looking forward? If you could give us some color there, then I will ask the follow-up.
Jay,我推算出 2026 年第 4 季隱含的有機營收成長率大約是負 3%,而且是在一個相對容易的比較基期之下。想請你談談這點:如果這個推算是正確的話,有沒有任何補充說明。然後更重要的是,這對未來的業務意味著什麼?如果你能提供一些顏色(補充)說明,我再問追問問題。
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
Sure. I think as we think about the fourth quarter, it really is important to take it in the context of the third and fourth quarter and also the full year. On the first half, we were down about 1 point. The third quarter was down a bit more than that. As we look at the third and fourth quarter together, we are talking about a full year growth rate leading to a decline of negative 1% to negative 2%. We historically see some seasonality with higher sales in the third quarter and then the fourth quarter.
當然。我認為在看第 4 季時,確實重要的是把它放在第 3 季與第 4 季、以及全年脈絡中一起看。上半年我們大約下滑 1 個百分點。第 3 季下滑幅度比那更大一些。當我們把第 3 季與第 4 季合在一起看,我們談的是全年成長率落在下滑負 1% 到負 2% 的區間。歷史上我們確實看到一些季節性:第 3 季銷售較高,接著是第 4 季。
In this particular case, with the promotional activity that we pursued in the third quarter, we are anticipating a third to fourth quarter decline in the high single-digit range. Very much in line with our expectations, although I would say the market and our performance has been a little bit better than our anticipation. Related to that, we always anticipated a deceleration in the fourth quarter versus the third. As we think about what this means for the overall health of the business, it really is important to consider it in the context of the third quarter as well.
在這個特定情況下,考量到我們在第 3 季所採取的促銷活動,我們預期第 3 季到第 4 季會出現高個位數百分比的下滑。這非常符合我們的預期,不過我會說市場與我們的表現其實比我們原先預估的稍微好一些。也因此,我們一直預期第 4 季相較第 3 季會出現減速。在思考這對整體業務健康度意味著什麼時,把它放在第 3 季的脈絡中一起看也很重要。
Jonathan Block - Analyst
Jonathan Block - Analyst
Then, I guess just to pivot, livestock continues to be the bright spot, pardon me, for you guys. You might exit 2026, or pardon me, 2026 might have a comp of high single digits. Maybe if you could just give us some thoughts on sustainability of livestock. Kristin, you mentioned the protein tailwinds, and that does not look like it is going away anytime soon. But just looking forward for this business off a high single-digit comp that might add some screwworm tailwinds in there, how do we think about that for 2027 and beyond?
那我想換個話題,畜牧業務持續是你們的亮點,不好意思。你們可能在 2026 年結束時,或不好意思,2026 年可能會面臨高個位數的比較基期。想請你談談畜牧業務的可持續性。Kristin,你提到蛋白質需求的順風,而這看起來短期內不會消失。但往前看,這項業務在高個位數比較基期之上,可能還會加上一些螺旋蠅(screwworm)的順風因素,我們該如何看待 2027 年及之後的走勢?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Yeah. We were quite pleased with the performance of livestock in the quarter. It grew 7% overall, and really underlying that, as you mentioned, is demand for quality protein, and that's really across the globe, I would say. We saw US delivering 5% to the quarter and international at 9% in the quarter. If you think about that, international livestock is a higher percentage of our business, as we've talked about, and that growth was really broad overall across species.
是的。我們對本季畜牧業務的表現相當滿意。整體成長 7%,而其背後的主要驅動,如你所提到的,是對高品質蛋白質的需求,我會說這是全球性的。我們看到美國本季貢獻 5%,國際市場本季為 9%。如果你這樣看,正如我們談過的,國際畜牧在我們業務中的占比更高,而這個成長在各物種之間也相當廣泛。
We are confident that livestock will remain a strong contributor. Obviously, as we see, there's definitely a little more cyclicality historically in livestock. It's influenced by disease, by weather, by outbreaks, local production cycles overall. But there were a few years, obviously, as you recall, where Zoetis had an LOE, and we also had African swine fever outbreaks.
我們有信心畜牧業務將持續是強勁的貢獻來源。當然,如我們所見,畜牧業務在歷史上確實存在較多一些的循環性。它會受到疾病、天氣、疫情爆發、以及各地整體生產週期的影響。但也有幾年,正如你所記得的,Zoetis 遇到專利到期(LOE),同時也發生非洲豬瘟疫情。
Historically, livestock is a solid contributor overall as an industry grower, and specifically for Zoetis, we're quite focused in our portfolio, as we've mentioned, around vaccines and genetics and preventatives, which we think has positioned us well as we see strong continued demand for protein.
從歷史來看,畜牧作為一個產業成長動能來源,整體而言是穩健的貢獻者;而就 Zoetis 而言,我們如先前所提,產品組合的重點非常聚焦在疫苗、基因育種與預防性產品上。我們認為,這讓我們在蛋白質需求持續強勁的情況下具備良好定位。
Operator
Operator
Brandon Vazquez, William Blair.
Brandon Vazquez,William Blair。
Brandon Vazquez - Analyst
Brandon Vazquez - Analyst
Kristin, I wanted to follow up on your commentary about you guys have been pretty successful, it seems like, in defending share in some of the gross-to-net promotional activities, maybe for lack of a better phrase to use there. The question being, do you think that these gross-to-net promotional activities are short-term in nature? Is this something you're doing to combat kind of temporary entrants from competitors, or do you think on a go-forward basis that you'll need to keep this new gross-to-net?
Kristin,我想追問你剛才的評論:看起來你們在一些「總額到淨額」(gross-to-net)的促銷活動上,似乎相當成功地守住了市占(如果用這個說法比較貼切的話)。問題是,你認為這些 gross-to-net 促銷活動是短期性質嗎?這是你們為了對抗競爭對手的暫時性新進者而採取的作法,還是你認為未來你們需要持續維持這種新的 gross-to-net 水準?
Part of the question is basically, what are the implications to your margins and your gross margins on a go-forward basis within the companion animal business?
部分問題其實是:在伴侶動物業務中,往前看這對你們的利潤率、以及毛利率會有哪些影響?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Yeah, I mean, it's a great question. I think our focus right now is with a lot of new entrants in both derm and parasiticides. Historically, as you know, in our space, when new entrants came, they expanded the market. We aren't seeing that right now, and so we've had to be a little more focused on some of these gross-to-net investments.
是的,我的意思是,這是個很好的問題。我認為我們目前的重點在於皮膚科(derm)與驅寄生蟲藥(parasiticides)兩個領域都有許多新進者。如你所知,歷史上在我們這個領域,新進者進來時通常會擴大市場。但我們現在沒有看到這種情況,因此我們必須在某些 gross-to-net 投入上更為聚焦。
Ultimately, we think when share settles out, and historically you've seen that somewhere between 12 and 18 months, and what we're really watching for to know how to tweak, and we're constantly watching every month, but certainly every quarter, is how are we seeing those shares stabilize? When we see two quarters where those shares pretty much stayed, we'll have a sense that those shares have stabilized, and we can then really focus more on gaining share and growing the market overall.
最終,我們認為當市占趨於穩定後——而歷史上你會看到這通常發生在 12 到 18 個月之間——我們真正關注、用來判斷如何調整的指標(我們每個月都在看,當然每一季也會看)是:我們看到這些市占如何趨於穩定?當我們看到連續兩季市占基本維持不變時,我們就會有把握認為市占已經穩定,接著就能更聚焦在提升市占並推動整體市場成長。
I don't think these are here forever, but I think as Jay mentioned in his remarks, I think some of these new products have only recently entered in certain markets, and this is a market-specific investment. We think we need to lap those new entrants for both derm and paras to really have a sense of how to continue to adjust our gross-to-net investments. But I think our strategy, as I mentioned earlier, is making sure at the very least we defend our share, and we're focused on both growing share and growing these markets ultimately.
我不認為這些會永遠存在,但如 Jay 在他的談話中提到的,我認為其中一些新產品只是最近才在某些市場進入,而這是一項因市場而異的投資。我們認為需要在皮膚科與驅寄生蟲藥兩個領域把這些新進者的影響「跑完一輪」(lap),才能真正掌握接下來如何持續調整我們的 gross-to-net 投入。但我認為我們的策略,如我先前提到的,是至少要確保守住市占,同時我們也聚焦在最終同時提升市占並擴大這些市場。
The reality is there are still way more untreated animals in both of these categories than there are treated animals. There's significant opportunity to do that, but I think as you combine both the competitive situation right now and macro, the market itself isn't growing as much, but we do continue to believe that that will happen ultimately as we get through this cycle.
現實是,在這兩個類別中,未接受治療的動物仍遠多於已接受治療的動物。在這方面有很大的機會,但我認為當你把目前的競爭態勢與總體環境一起考量時,市場本身的成長沒有那麼快;不過我們仍然相信,隨著我們度過這個週期,最終這件事會發生。
Brandon Vazquez - Analyst
Brandon Vazquez - Analyst
Okay. On Lenivia, I just want to hit on that for a second because that feels like clearly one of the areas you guys are still kind of innovators and a fast leader there. Early days of Lenivia, I don't know how many pilot accounts you might be having, but any metrics, any anecdotal feedback you want to share with us just in terms of, is this the product you think through 2027 might be able to start to re-accelerate the OA pain management section? Thanks.
好的。關於 Lenivia,我想稍微提一下,因為這顯然是你們仍屬於創新者、而且在那裡是快速領先者的領域之一。Lenivia 的早期階段,我不確定你們可能有多少試點客戶,但就任何指標或軼事性回饋,你們願意跟我們分享嗎?特別是就你們是否認為,這個產品在 2027 年前後可能開始重新加速 OA 疼痛管理板塊?謝謝。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Yeah. We are quite excited on the performance of both Lenivia and Portela, which is the long-acting for cats. We have launched across a number of markets in the EU and Canada, and what we are hearing right now, again, I would like to be clear, this is obviously early days, but the veterinarian satisfaction is high at 97% for Lenivia and about 95% for Portela. Pet owner satisfaction is high at 98%. And what we are seeing is what we expected, which is that Lenivia and Portela are providing a really good opportunity to grow the market.
是的。我們對 Lenivia 以及 Portela(貓用長效型)兩者的表現都相當興奮。我們已在歐盟多個市場與加拿大上市;我們目前聽到的回饋是——我想先說清楚,這顯然仍在早期——獸醫對 Lenivia 的滿意度高達 97%,對 Portela 約為 95%。飼主滿意度也很高,達到 98%。而我們看到的情況符合預期:Lenivia 與 Portela 正在提供一個非常好的機會來擴大市場。
Having a product that is more convenient, that is once every three months, has really helped expand the market. Obviously, we have seen some cannibalization, as you saw, but as you looked overall at OA pain and international, we saw growth, and that has really been driven by Lenivia and Portela and sort of the positive both veterinarian and pet owner uptake of those products. We continue to expect approval of Lenivia in the US in 2027, so we will be excited to bring that product to the US as well.
擁有一個更便利、每三個月施用一次的產品,確實有助於擴大市場。當然,我們也看到一些自我侵蝕(如你所見),但若整體來看 OA 疼痛與國際市場,我們看到了成長,而這主要是由 Lenivia 與 Portela 所帶動,以及獸醫與飼主對這些產品的正向採用所驅動。我們仍預期 Lenivia 會在 2027 年於美國獲批,因此我們也很期待把這個產品帶到美國。
Operator
Operator
Erin Wright, Morgan Stanley.
Erin Wright,摩根士丹利。
Erin Wright - Analyst
Erin Wright - Analyst
I am curious if you are seeing, and I will ask both mine upfront, but are you seeing continuing stabilization in the share loss through the fourth quarter, and should we anticipate any changes to the pricing and promotion strategy? You did a promotion in August, September. Seems like you feel okay with that. Do you double down? Are you doing more in terms of pricing or promotions on that front? And are you seeing also a competitive response, a lack of competitive response? You could potentially see stabilization quicker than expected.
我想了解你們是否看到市占流失在第四季持續趨於穩定;我先把兩個問題一起問:你們是否預期定價與促銷策略會有任何變化?你們在 8 月、9 月做了促銷。看起來你們對此感覺還不錯。你們會加碼嗎?在定價或促銷方面,你們是否會做更多?另外,你們是否也看到競爭對手的回應,或缺乏競爭回應?你們可能會比預期更快看到穩定。
My second question is more on margins and into next year, and what does this all mean from a margin standpoint, and what are maybe some of the mitigating factors we should consider on the cost side? Jay, as you look at this business and you think about some of those opportunities from an efficiency perspective, how do you think about that?
我的第二個問題更多是關於毛利率以及展望到明年:從毛利率角度來看,這一切意味著什麼?在成本端有哪些我們應該考量的緩解因素?Jay,當你看這個業務並思考效率面的機會時,你怎麼看?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Thanks, Erin. I'll take your first question, and I'll let Jay take your second. As we spoke about, we are pleased with the performance of the promotions. We are adjusting month by month, quarter by quarter with those plans.
謝謝你,Erin。我先回答第一個問題,第二個問題我讓 Jay 來回答。如同我們提到的,我們對促銷的表現感到滿意。我們會按月、按季調整這些計畫。
As I said, we're going to watch overall share and look for overall stabilization. But we also need to be cognizant of when new products will be entering or when supply will be expanding in some of these markets. So although we're pleased to move from a negative 7 to negative 4 as we talk about derm share loss overall from Q2 to Q3, our goal is to get that to zero and to be growing back, to be clear. So we'll continue to watch that. We're pleased that we are slowing that decline right now.
如我所說,我們會觀察整體市占並尋求整體趨於穩定。但我們也必須留意,在某些市場何時會有新產品進入,或供給何時會擴大。因此,雖然我們很高興皮膚科(derm)整體市占流失從第二季到第三季由負 7 改善到負 4,但我們的目標是把它拉回到 0,並且要恢復成長——我想說清楚。所以我們會持續關注。我們很高興目前正在放緩這個下滑。
Our goal, obviously, is to get that to stabilization on that share, and importantly, to get that stabilization to as high a share as we possibly can. We'll continue to look at the promos we think help drive that. We do like this focus on gross-to-net versus list, because it helps us make sure that we have clear outcomes to the programs that we run, clear metrics we can see that we're delivering.
我們的目標,當然,是讓市占趨於穩定;更重要的是,讓這個穩定發生在我們能達到的盡可能高的市占水準上。我們會持續檢視那些我們認為有助於推動此目標的促銷活動。我們確實喜歡把重點放在 gross-to-net(毛到淨)而非牌價(list),因為這能幫助我們確保所執行的方案有明確成果,並且有清楚的指標可用來衡量我們是否交付成效。
As we think about some of those overall programs, they're really focused on things like measuring new auto-ship starts, new patient starts, loyalty at the clinic. We'll continue to invest in those. We have obviously seen some competitive responses as we expect, but nothing that we weren't expecting overall. We'll continue to monitor it and provide an update as we get to Q4 on the continued strategy here.
當我們思考這些整體方案時,它們主要聚焦在例如衡量新的自動配送(auto-ship)啟動數、新病患啟動數、以及診所端的忠誠度等。我們會持續投資這些項目。我們確實如預期看到一些競爭回應,但整體而言沒有超出我們的預期。我們會持續監測,並在進入第四季時就這裡的持續策略提供更新。
Jay, do you want to take the second question?
Jay,你要回答第二個問題嗎?
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
Sure. Just overall, as we think about margins, the full year margin is shaping up in line or better than our expectations. We are pleased with the progress on both the competitive initiatives we put in place, but also the cost initiative. You will note SG&A declined 1% on an overall basis as we expect from an overall year standpoint.
當然。整體來看,從毛利率角度,全年毛利率走勢與我們的預期一致或更好。我們對我們所推動的競爭應對措施,以及成本措施的進展都感到滿意。你會注意到,SG&A(銷售、一般及行政費用)在整體基礎上下降了 1%,這也符合我們對全年層面的預期。
Now, it is important not to look at the fourth quarter in isolation. Some of the comments I made relative to revenue impact not only gross margin, but also impact SG&A leverage in the quarter. So you have to look at it in a broader context, second half or even more broadly than that.
另外,很重要的一點是不要孤立地看第四季。我先前提到的、與營收影響相關的一些評論,不僅會影響毛利率,也會影響該季 SG&A 的槓桿效應。因此你必須在更廣的脈絡下來看,例如下半年,甚至更長的期間。
Now, as we go to next year, there is a couple of drivers that we are going to be very focused on. First of all, we do have a world-class manufacturing and supply chain organization. I have been really impressed with the work that that team is doing. The amount of manufacturing and product that we have is just astounding. Using that as a competitive advantage, especially in this environment, I think can be really, really important to our success over time, but also in 2027.
接著看明年,我們會非常聚焦幾個驅動因素。首先,我們擁有世界級的製造與供應鏈組織。我對那個團隊所做的工作印象非常深刻。我們的製造能力與產品供應量之大,確實令人驚訝。在這樣的環境下,把這點作為競爭優勢,我認為對我們長期成功、以及 2027 年的表現,都可能非常、非常重要。
Secondly, I noted SG&A declines this year. As we look to next year, we will continue to focus on savings initiatives. We have opportunity. We have pursued some cost savings initiatives this year. We will have further impact from those next year.
第二,我提到今年 SG&A 下降。展望明年,我們會持續聚焦節省成本的計畫。我們有機會。今年我們已推動一些成本節省措施。明年我們會從這些措施中看到更進一步的影響。
At the same time, we will continue to invest in R&D for success. I think one of the things I have walked away from over the last several months, the remarkable pipeline that we have in place. So we are going to fund those initiatives for success. There will be some benefit in 2027, but much more prominent 2028 and 2029. So we will fund those for success, but really target gross margin and SG&A, or cost of goods and SG&A as areas where we focus our initiatives on.
同時,我們也會持續投資研發(R&D)以確保成功。我在過去幾個月最大的體會之一,是我們現有產品管線的卓越程度。因此我們會為這些計畫提供資金以確保成功。在 2027 年會有一些效益,但在 2028 與 2029 年會更為顯著。所以我們會為成功提供資金,但會把毛利率與 SG&A——或銷貨成本與 SG&A——作為我們推動各項措施的重點領域。
Operator
Operator
Matt Dellatorre, Goldman Sachs.
Matt Dellatorre,高盛。
Matt Dellatorre - Analyst
Matt Dellatorre - Analyst
Maybe just on derm, if we look at the franchise sales decline, could you just help us break out how that splits between volume and some of the price gross-to-net promotions? Then, in the last quarter, you all highlighted that retail channel growth had moderated versus prior being more of an offset to some of the clinic weakness. Could you just give us an update there on what you're seeing, and if the outlook has improved at all?
或許先就皮膚科(derm)來問,如果我們看到該事業線銷售下滑,能否請你們協助拆解一下,其中有多少來自銷量(volume),以及有多少來自價格端的毛額到淨額(gross-to-net)促銷?另外,在上一季你們提到零售通路成長相較先前有所趨緩,先前它更像是在抵銷部分診所端的疲弱。能否請你們更新一下目前看到的情況,以及展望是否有任何改善?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure. I'll let Jay take some of the specifics on the derm breakout you're looking on volume versus price, and then I can take the second. I'll start on that one, and then Jay can take the one on derm. What we saw in the quarter overall is the retail sector, whether you think of both online and in-store, if you compare it to 2025, that growth has slowed. Home delivery, on the other hand, has been stronger as we looked at it.
好的。我先請 Jay 針對你們想了解的皮膚科拆分(銷量對比價格)提供一些細節,然後第二個問題我來回答。我先從那題開始,接著 Jay 再回答皮膚科那題。我們在本季整體看到的是,零售端——不論是線上或實體——若與 2025 年相比,成長已放緩。相對地,居家配送(home delivery)在我們觀察下表現更強。
What we were very pleased with in the quarter that I think helped contribute to the defense of both Simparica and derm is real investments in retail, re-looking at our MAP pricing there, which I think has has really strengthened us in the retail channel overall. So we're continuing to invest there. a lot of pet owners find that quite convenient.
我們本季非常滿意的一點,我認為也有助於支撐 Simparica 與皮膚科業務的,是我們在零售端的實質投資,重新檢視我們的 MAP(最低廣告價格)定價,我認為這確實強化了我們在整體零售通路的競爭力。因此我們會持續在那裡投資。許多飼主覺得那相當便利。
We're seeing advantages to compliance there overall. So we'll continue to invest in that sector. I think overall, given it's had such strong number of years, that growth is slowing a little bit, with more of that getting made up more recently, as you think about home delivery. But I don't know if you want to take the question on derm.
我們也看到在依從性(compliance)方面整體有優勢。所以我們會持續投資該領域。我認為整體而言,鑑於零售端過去幾年表現非常強勁,成長正在稍微放緩;而近期更多的成長補上來自居家配送。不過我不知道你是否想回答皮膚科那題。
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
Sure. So overall, as we think about the entire third quarter performance, we highlighted in our remarks earlier roughly flat volume with down 1% or so in price. Dermatology had a little bit more of a prominent impact than that from a pricing standpoint, but overall, the franchise was down 16%.
好的。整體來看第三季表現,我們先前在談話中提到,銷量大致持平,而價格約下滑 1% 左右。從定價角度看,皮膚科的影響稍微更顯著一些,但整體該事業線下滑 16%。
Price contributed, and it was higher than the corporate average price decline, with volume down the lion's share of it, though. So really, that's the shape of the trajectory. As we think about the pricing changes, really, it was virtually all, in fact, it was all gross-to-net investments that we made versus any changes to list price across the portfolio of derm.
價格確實有貢獻,而且其降幅高於公司整體平均的價格下滑;不過其中大部分仍來自銷量下滑。所以大致就是這樣的走勢輪廓。至於定價變動,基本上幾乎全部——事實上就是全部——都來自我們做出的毛額到淨額(gross-to-net)投資,而非皮膚科產品組合中任何標價(list price)的調整。
Operator
Operator
Navann Ty, BNP Paribas.
Navann Ty,法國巴黎銀行(BNP Paribas)。
Navann Ty - Analyst
Navann Ty - Analyst
Can you discuss further the international companion animal performance, which was flat this quarter? Have you seen more competitive or macro pressure there? Then in OA pain, if you could discuss cannibalization in the markets where you have launched Lenivia and Portela. Maybe my last question on the breakthrough innovation pipeline, if you are on track for the late 2027 approval.
能否進一步談談國際伴侶動物業務本季表現持平的原因?你們是否看到更大的競爭壓力或總體環境壓力?另外在 OA 疼痛領域,能否談談在已推出 Lenivia 與 Portela 的市場中,是否出現產品互相侵蝕(cannibalization)?最後一題關於突破性創新(breakthrough innovation)研發管線,你們是否仍按計畫在 2027 年底取得核准?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure. I will start on the first, and Jay, you can let me know if you have anything you want to build. We did see flat growth overall in international in the quarter. That really had to do with similar trends that you might have seen in some of the developed markets in Europe with pressure overall on derm. We did see strong growth overall in parasiticides there.
好的。我先回答第一題;Jay,如果你有想補充的再告訴我。我們確實看到本季國際市場整體成長持平。這主要與你在歐洲部分已開發市場可能看到的類似趨勢有關,也就是皮膚科整體承壓。不過我們在驅寄生蟲產品(parasiticides)方面看到整體強勁成長。
I think some of the same sort of trends we have been seeing overall in markets where we have had new competitors entering. If you go market by market, obviously there, you have to see that the timing may obviously switch overall. I think your second question was on breakthrough innovation, I believe. We are very excited, as Jay said, around our innovation.
我想這也反映了我們在一些市場中持續看到的相同趨勢:有新競爭者進入。若逐一看各市場,當然你會看到時點可能會有所不同、整體表現也會隨之切換。我想你的第二個問題是關於突破性創新,對嗎?我們對創新非常振奮,正如 Jay 所說。
As we mentioned, we are committed to achieving a significant major market approval every year for the next several years. We were really pleased that all the milestones that we have outlined for 2026 are on track, and we have got a few that have moved forward. We will see a number of launches of some of these products into 2027.
如我們提到的,我們承諾在未來幾年每年都要取得一項重要主要市場的核准。我們很高興,針對 2026 年我們所列出的所有里程碑都按計畫進行,而且其中有幾項還提前推進。我們將在 2027 年推出其中若干產品。
We will see those ramp as they go through the year, obviously. But also very excited, to your point, on the breakthrough innovation. Those are the creation of new categories, as we outlined in some of our slides. That is around conditions such as chronic kidney disease, cardiology, oncology, obesity, diabetes, anxiety.
顯然,這些產品會在年度進程中逐步放量(ramp)。同時也如你所提到的,我們對突破性創新也非常興奮。這些是我們在部分投影片中所說的「創造新類別」。涵蓋的疾病/領域包括慢性腎臟病、心臟科、腫瘤科、肥胖、糖尿病、焦慮等。
These are important new categories where there are very limited products out there today. This is something that Zoetis has always been known for, really creating new categories and bringing innovation. We remain quite excited on all these. Importantly, we look forward to sharing a more comprehensive update to that pipeline at JPMorgan, where we will update all the sort of expectations as we look at the years to come.
這些都是重要的新類別,而目前市面上的產品非常有限。這也是 Zoetis 一直以來著稱之處:真正去創造新類別並帶來創新。我們對這些項目都仍然相當振奮。更重要的是,我們期待在摩根大通(JPMorgan)會議上分享對該研發管線更全面的更新,屆時我們也會更新對未來幾年的各項預期。
Operator
Operator
Christopher LoBianco, TD Cowen.
Christopher LoBianco,TD Cowen。
Christopher LoBianco - Equity Analyst
Christopher LoBianco - Equity Analyst
We had two. First, can you quantify the impact of any one-time factors or one-offs in the quarter, like stocking or one-time purchases? Second, can you provide any color on the product profile of Simparica Duo? Is this product meant for RX or OTC usage?
我有兩題。第一,能否量化本季任何一次性因素或一次性項目的影響,例如補庫(stocking)或一次性採購?第二,能否提供一些關於 Simparica Duo 產品定位的資訊?這個產品是用於處方藥(RX)還是非處方藥(OTC)?
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
James Saccaro - Executive Vice President, Chief Financial Officer, Chief Operating Officer
Sure. As it relates to one-time items, really in the third quarter, we did have the promotional activity that I commented on, and that really impacts the shape of sales growth between the third and fourth quarters. That is something that we periodically do. You will recall we have done these in past years. As we evaluate 2027, we will evaluate the appropriate promotional activity.
好的。關於一次性項目,第三季我們確實有我先前提到的促銷活動,而這確實影響了第三季與第四季之間銷售成長的形狀/分布。這是我們會定期進行的事情。你們也記得我們過去幾年做過這類活動。在我們評估 2027 年時,也會評估適當的促銷活動安排。
But beyond that, which did sort of impact the sales contour between Q3 and Q4, there were really no one-time items to point out. Like I say, that is something that we will evaluate next year, what is the right shape of promotions as we go through the year. As it relates to the product profile-
但除此之外——也就是那個在某種程度上影響 Q3 與 Q4 銷售輪廓的因素——其實沒有其他一次性項目需要特別指出。如我所說,這是我們明年會評估的:在年度推進過程中,促銷的正確節奏/形狀應該是什麼。至於產品定位——
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Yeah. For Duo, we are quite excited to expect approval for Duo this year and launch it next year. It will be an RX product. It is not an over-the-counter product. It will be part of the Simparica family.
是的。對於 Duo,我們非常期待今年能取得核准,並在明年上市。它會是一個處方藥(RX)產品。不是非處方藥(over-the-counter)。它將成為 Simparica 家族的一部分。
The focus of this product is meeting an unmet need, which is, there are many areas of the country where there are fleas, ticks, and intestinal worms, but heartworm is not a major area, or areas where heartworm is huge and they want to move to our product ProHeart, and it really meets that need. So it is a product really focused on fleas, ticks, and intestinal worms. So we are excited to get approval there and then add this to our overall Simparica family.
這個產品的重點在於滿足未被滿足的需求:在全國許多地區有跳蚤、蜱蟲與腸道寄生蟲,但心絲蟲並不是主要問題;或者在心絲蟲非常嚴重、他們希望改用我們 ProHeart 產品的地區——它都能滿足那樣的需求。因此它是一個真正聚焦於跳蚤、蜱蟲與腸道寄生蟲的產品。所以我們很期待取得核准,並把它納入我們整體的 Simparica 產品家族。
Operator
Operator
Andrea Alfonso, UBS.
Andrea Alfonso,瑞銀(UBS)。
Andrea Alfonso - Analyst
Andrea Alfonso - Analyst
My question was really, I appreciate all the color that you provided on sort of the competitive, defending against the competition by channel. I guess, any color on the efforts by channel? How does it vary between retail versus independents, and how do we think about the competitive intensity there? Then I guess separately, I will squeeze this in, is with two big distributors coming together imminently, how are you approaching distributor relationships versus more direct engagement with practices?
我的問題其實是,我很感謝你們就各通路如何競爭、防禦競爭對手所提供的各種細節。我想問的是,能否再補充一些各通路的具體作法?在零售通路與獨立通路之間有何差異?我們該如何看待那裡的競爭強度?另外我也想順便問一下,隨著兩家大型經銷商即將合併,你們在經銷商關係的經營上,與更直接地與診所/醫療團隊互動相比,是如何取捨與布局的?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure. I will take those questions as a comprehensive, because I think what you are really talking about overall is channel. I think, as we think, you have to pay attention to all those. Obviously, we have had a strength in the corporate side historically. We will continue to invest there.
好的。我會把這些問題當作一個整體來回答,因為我認為你真正談的是整體的通路策略。我認為在思考時,你必須關注所有這些面向。很明顯地,我們過去在企業端(corporate)一直有優勢。我們會持續在那裡投資。
We think there is still a lot more that our teams are focused there on making sure if there is, if we are one of two, we want to be the largest there. So there are very targeted promotions meeting each of those individual corporate strategies there. It is also focusing on independents. We have a loyalty program there that we are quite focused on. That is obviously part of our targeted promotions, as we talked about, is how do we gain share in some of those independents. So we will be focused there.
我們認為團隊在那裡仍有很多可以著力之處,確保如果市場格局是二選一,我們要成為其中最大的那一個。因此會有非常精準的促銷方案,去對應各個企業客戶各自的策略。同時也會聚焦在獨立通路。我們在那裡有一個忠誠度計畫,我們相當專注。這顯然也是我們所談到的精準促銷的一部分:我們如何在部分獨立通路中提升市占。所以我們也會在那裡持續聚焦。
We talked a lot about investing in retail, where you get an opportunity for auto-ship. There's really great movements as well in the box store side as well. These are all important. As we think about distribution, they've always been an important channel for us. Some of our customers prefer to place one order across all those. We're going to continue to and make sure that we're available wherever both the vet and the pet owner wants to access our products. We'll look at channels holistically and make sure we have a targeted strategy to meet each of those different channels' needs.
我們也談了很多在零售端的投資,因為那裡有自動配送(auto-ship)的機會。在大型賣場(box store)端也有非常好的進展。這些都很重要。就經銷(distribution)而言,它們一直是我們的重要通路。我們的一些客戶偏好一次下單就涵蓋所有品項。我們會持續確保無論獸醫或飼主想透過哪種方式取得我們的產品,我們都能供應到位。我們會以整體角度檢視各通路,並確保有針對性的策略來滿足不同通路的需求。
Operator
Operator
Steven Dechert, KeyBanc Capital Markets.
Steven Dechert,KeyBanc 資本市場。
Steven Dechert - Equity Analyst
Steven Dechert - Equity Analyst
I guess just on the gross-to-net investments on the vet clinic side, were you in the process of the product bundling with clinics? Have you mainly worked through all those contracts, and how often can you revisit those contracts for further changes? On key derm internationally, on their organic growth being down 20%, a little worse maybe than we expected. I guess Numelvi and Zenrelia have been in that market in Europe for a while, so I guess just maybe what changed this quarter with the competitive dynamic?
我想先問獸醫診所端的毛利到淨額(gross-to-net)投資:你們是否正在與診所進行產品組合(bundling)?你們是否已經大致完成這些合約的處理?以及你們多久能重新檢視這些合約、進一步調整?另外,關於 Key Derm 的國際業務,其有機成長下滑 20%,可能比我們預期稍差一些。我理解 Numelvi 和 Zenrelia 在歐洲市場已經存在一段時間了,所以想請教本季競爭態勢有什麼變化?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure. Your first question on gross-to-net and product bundling. We have always had a broad portfolio. We have the broadest portfolio. We've always been able to leverage that portfolio as we think about overall promotions. We're going to continue to do that.
好的。你第一個問題是關於毛利到淨額(gross-to-net)與產品組合(bundling)。我們一直都有很廣的產品組合。我們擁有最廣的產品組合。在思考整體促銷時,我們一直能夠運用這個產品組合的優勢。我們會持續這麼做。
As we think about some of those clinics, we look at our overall share there. We try to make sure that they're buying across our portfolio. I think that will remain, Steve, an important strategy for us. We're obviously seeing some competitors try to copy that where they can, but they don't have as broad a portfolio. Importantly, as we've talked about before, it's really the innovation that we bring that pulls this forward.
在看待部分診所時,我們會檢視我們在那裡的整體市占。我們會努力確保他們在我們的產品組合中進行跨品項採購。我認為這將會持續是我們的重要策略,Steve。我們確實看到一些競爭對手在能力所及的範圍內嘗試複製,但他們的產品組合沒有我們這麼廣。更重要的是,如同我們之前談過的,真正推動這一切向前的是我們帶來的創新。
As we think about the approvals we had this year and all the launches we are going to have next year, I think that sets up that portfolio play that we are talking about. We look at each of those programs on a quarter-by-quarter basis. The contracts, as you think about some of the corporates, each contract is slightly different. Normally, there are two-to-three-year contracts, where you can obviously revisit those. But we are very pleased with how we are positioned there.
當我們回顧今年取得的核准,以及明年將推出的所有新品,我認為這為我們所談的產品組合策略奠定了基礎。我們會以每季為單位檢視各項方案。至於合約,若你想到一些企業客戶(corporates),每份合約都略有不同。通常是兩到三年的合約,當然也可以在期間重新檢視。但我們對目前在那裡的布局位置非常滿意。
Again, I think our innovation is what really differentiates us overall. Your question on derm and international. You were referencing Europe, where we have had some of that competition for a while, but international is quite broad, as you know, and I think the competitive dynamics are quite different in different markets. As you think about even some of our top five markets, if you pull in, say, Brazil or Australia, in some of those markets, these are products that are sold almost like over the counter in retail stores, where the strategies are quite different.
再說一次,我認為我們的創新才是整體上真正讓我們與眾不同的地方。你關於皮膚科(derm)與國際市場的問題。你提到的是歐洲;如你所知,我們在那裡面對部分競爭已經有一段時間了,但國際市場的範圍很廣,而且不同市場的競爭態勢差異很大。即便看我們前五大市場,如果把巴西或澳洲納入,在其中一些市場,這些產品幾乎像是非處方(OTC)一樣在零售店販售,因此策略也非常不同。
I think some of our competitors are positioned a little differently than us, as well as some of those pricing dynamics in some of those other markets. So yes, Europe might look a little bit more in some of the markets like the US, but as you get outside of Europe, those market dynamics are quite unique in certain large markets that are top five markets for us, such as, say, Brazil or Australia.
我認為部分競爭對手的定位與我們略有不同,另外在其他一些市場也存在不同的定價動態。所以是的,歐洲在某些市場看起來可能更像美國,但當你走出歐洲之外,對我們而言屬於前五大市場的一些大型市場(例如巴西或澳洲),其市場動態在某些方面相當獨特。
Operator
Operator
Thank you. There are no further questions in queue. I will now turn the call back over to CEO Kristin Peck for any additional or closing remarks.
謝謝。目前沒有其他排隊提問。我現在把電話交回給執行長 Kristin Peck,請她做任何補充或結語。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Well, thanks, everyone, for joining us today. As always, we really appreciated your questions and your continued interest in Zoetis, and we look forward to keeping you updated at future conferences and seeing you again on the Q4 call next year. Thanks, everybody.
好的,謝謝各位今天加入我們。一如既往,我們非常感謝各位的提問,以及你們對 Zoetis 的持續關注;我們也期待在未來的會議持續向各位更新,並在明年第四季(Q4)電話會議上再次與各位見面。謝謝大家。
Operator
Operator
Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.
謝謝。今天的會議到此結束。感謝各位撥冗與會。您現在可以斷線。